La d A 30-year-old male is found to be positive for HBsAg and HBeAg and is diagnosed with chronic hepatitis B. The patient’s viral load was 2x 100000 and SGPT is found to be doubled. What is the appropriate management in this patient? SGPT-Serum glutamate pyruvate transaminase

Correct Answer: D. Tenofovir for> 40 weeks

This patient meets criteria for antiviral therapy initiation in chronic hepatitis B: HBsAg and HBeAg positivity (indicating active viral replication), elevated viral load (2×10⁵ copies/mL, well above the 2×10⁴ threshold for treatment consideration), and elevated transaminases (SGPT doubled). According to Indian guidelines (AASLD, EASL, and adapted by IASL) and standard practice in India, tenofovir is the first-line nucleotide reverse transcriptase inhibitor (NtRTI) for HBeAg-positive chronic hepatitis B because it has superior barrier to resistance, potent viral suppression, and excellent long-term efficacy. The duration of >40 weeks (typically 48–52 weeks or longer) reflects the standard treatment course for HBeAg-positive disease, with the goal of HBeAg seroconversion and sustained virological response. Tenofovir monotherapy is preferred over lamivudine monotherapy due to the high rate of lamivudine resistance (70% at 5 years). The combination with interferon is reserved for specific scenarios (HBeAg-positive with low viral load, or when rapid HBeAg clearance is desired), not for this high viral load presentation.

Why the other options are wrong

A. Combined pegylated interferon with lamivudine — This is wrong because combination therapy is not standard first-line for HBeAg-positive disease with high viral load (>2×10⁵). Pegylated interferon is reserved for selected cases (low viral load, HBeAg-positive, or to achieve rapid HBeAg seroconversion in motivated patients). Lamivudine monotherapy has unacceptably high resistance rates (>70% at 5 years), making it obsolete as first-line therapy in India. The NBE trap here is pairing 'combination' with 'better efficacy,' when in fact monotherapy with a high-barrier agent (tenofovir) is superior. B. Lamivudine for 30+ weeks — This is wrong because lamivudine is no longer recommended as monotherapy for chronic hepatitis B in India or globally due to rapid emergence of resistance mutations (YMDD variants). Although lamivudine was used historically, it is now relegated to salvage therapy or combination regimens only. The 30-week duration is also suboptimal; standard therapy is ≥48 weeks. The NBE trap is offering a 'nucleoside' option that students may recall from older textbooks, but current Indian practice and IASL guidelines mandate nucleotide agents (tenofovir, entecavir) as first-line. C. Pegylated interferon for 52 weeks — This is wrong because pegylated interferon monotherapy is not first-line for HBeAg-positive disease with high viral load (2×10⁵). Interferon is considered in HBeAg-positive patients with low viral load (<2×10⁵), normal or mildly elevated ALT, or when rapid HBeAg clearance is desired and patient is motivated. The high viral load in this case makes interferon less likely to achieve HBeAg seroconversion. The NBE trap is offering a 'standard 52-week course' that sounds authoritative but ignores the critical role of baseline viral load in treatment selection.

High-Yield Facts

Mnemonics

HBeAg+ Treatment Selection: VIRAL LOAD MATTERS High viral load (>2×10⁴) → Tenofovir/Entecavir monotherapy (NtRTI). Low viral load (<2×10⁴) → Consider pegylated interferon (if motivated, rapid clearance desired). Always check ALT: if elevated, treat regardless of viral load threshold. Use this to avoid the trap of offering interferon for high viral load cases. Resistance Hierarchy: LAMIVUDINE IS DEAD Lamivudine = 70% resistance at 5 years (obsolete). Adefovir = moderate resistance. Tenofovir/Entecavir = <1% resistance at 5 years (first-line). In India, tenofovir is preferred due to cost-effectiveness and availability; entecavir is alternative if renal function is borderline.

NBE Trap

NBE pairs 'combination therapy' (option A) and 'lamivudine' (option B) with plausible-sounding durations to trap students who confuse older treatment paradigms with current guidelines. The key discriminator is recognizing that high viral load + HBeAg positivity mandates a high-barrier NtRTI (tenofovir), not lamivudine or interferon-based regimens.

Clinical Pearl

In Indian practice, a 30-year-old with HBeAg-positive chronic hepatitis B and high viral load is a candidate for long-term antiviral therapy to prevent cirrhosis and hepatocellular carcinoma. Tenofovir is the backbone of therapy because it is potent, has minimal resistance, and is now affordable in India through generic formulations—making it the de facto standard in government and private practice.

_Reference: Harrison Ch. 295 (Chronic Hepatitis B); IASL Guidelines on Chronic Hepatitis B Management (adapted from AASLD 2018); KD Tripathi Ch. 61 (Antivirals)_